Search Results for: LRP1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CCN2 cellular communication network factor 2
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • RUNX3 regulates YAP1-mediated transcription
CD82 CD82 molecule
CLU clusterin
  • Platelet degranulation
  • Terminal pathway of complement
  • Antimicrobial peptides
  • Regulation of Complement cascade
  • Zinc
  • Copper
  • Zinc acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
CTSG cathepsin G
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Metabolism of Angiotensinogen to Angiotensins
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Interleukin-1 processing
  • Neutrophil degranulation
  • Antimicrobial peptides
  • Suppression of apoptosis
  • Purinergic signaling in leishmaniasis infection
  • Bis-Napthyl Beta-Ketophosphonic Acid
  • 2-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic Acid
DAB1 DAB adaptor protein 1
  • Reelin signalling pathway
DAB2 DAB adaptor protein 2
  • Gap junction degradation
  • Formation of annular gap junctions
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
DLG4 discs large MAGUK scaffold protein 4
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
  • Guanidine
  • Guanosine-5'-Monophosphate
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Respiratory syncytial virus (RSV) attachment and entry
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Poziotinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Mobocertinib
  • Almonertinib
  • Amivantamab
  • Laryngeal cancer
  • Cervical cancer
  • Oral cancer
  • Gastric cancer
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Bladder cancer
ELANE elastase, neutrophil expressed
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Pyroptosis
  • Neutrophil degranulation
  • Antimicrobial peptides
  • Regulation of Complement cascade
  • Expression of NOTCH2NL genes
  • Alpha-1-proteinase inhibitor
  • Mdl 101,146
  • Freselestat
  • Elafin
  • Lupeol
  • Ursolic acid
  • Neutropenic disorders, including the following three diseases: Kostmann syndrome; Cyclic neutropenia; X-linked neutropenia/myelodysplasia
F8 coagulation factor VIII
  • Platelet degranulation
  • Intrinsic Pathway of Fibrin Clot Formation
  • Common Pathway of Fibrin Clot Formation
  • Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation
  • COPII-mediated vesicle transport
  • Cargo concentration in the ER
  • Defective factor IX causes thrombophilia
  • Defective F8 accelerates dissociation of the A2 domain
  • Defective F8 cleavage by thrombin
  • Defective F8 binding to von Willebrand factor
  • Defective F8 binding to the cell membrane
  • Defective cofactor function of FVIIIa variant
  • Defective F8 secretion
  • Defective F9 variant does not activate FX
  • Defective F8 sulfation at Y1699
  • Drotrecogin alfa
  • Coagulation Factor IX (Recombinant)
  • TB-402
  • Thrombin
  • Protein C
  • Human thrombin
  • Thrombin alfa
  • Vonicog alfa
  • Von Willebrand factor human
  • Anti-inhibitor coagulant complex
  • Coagulation Factor IX Human
  • Nonacog beta pegol
  • Damoctocog alfa pegol
  • Rurioctocog alfa pegol
  • Hemophilia; Hemophilia A (HEMA); Hemophilia B (HEMB); von Willebrand disease (VWD)
F9 coagulation factor IX
  • Extrinsic Pathway of Fibrin Clot Formation
  • Intrinsic Pathway of Fibrin Clot Formation
  • Gamma-carboxylation of protein precursors
  • Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
  • Removal of aminoterminal propeptides from gamma-carboxylated proteins
  • Protein hydroxylation
  • Defective factor IX causes thrombophilia
  • Defective cofactor function of FVIIIa variant
  • Defective F9 variant does not activate FX
  • Defective F9 secretion
  • Defective F9 activation
  • Defective gamma-carboxylation of F9
  • Antihemophilic factor, human recombinant
  • Menadione
  • TTP889
  • Turoctocog alfa
  • Kappadione
  • Coagulation factor VII human
  • Antihemophilic factor human
  • Emicizumab
  • Lonoctocog alfa
  • Moroctocog alfa
  • Turoctocog alfa pegol
  • Hemophilia; Hemophilia A (HEMA); Hemophilia B (HEMB); von Willebrand disease (VWD)
FURIN furin, paired basic amino acid cleaving enzyme
  • Signaling by NODAL
  • Collagen degradation
  • Collagen degradation
  • Elastic fibre formation
  • Activation of Matrix Metalloproteinases
  • Removal of aminoterminal propeptides from gamma-carboxylated proteins
  • NGF processing
  • Synthesis and processing of ENV and VPU
  • Signaling by PDGF
  • Pre-NOTCH Processing in Golgi
  • TGF-beta receptor signaling activates SMADs
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Uptake and function of anthrax toxins
  • Formation of the cornified envelope
  • Assembly of active LPL and LIPC lipase complexes
  • CD163 mediating an anti-inflammatory response
  • Potential therapeutics for SARS
  • Attachment and Entry
  • Induction of Cell-Cell Fusion
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Amyloid fiber formation
  • Respiratory syncytial virus (RSV) attachment and entry
  • Maturation of hRSV A proteins
  • Capric acid
GIPC1 GIPC PDZ domain containing family member 1
  • FGFR1b ligand binding and activation
  • FGFR1c ligand binding and activation
  • TGFBR3 regulates TGF-beta signaling
  • TGFBR3 regulates FGF2 signaling
GTPBP1 GTP binding protein 1
GULP1 GULP PTB domain containing engulfment adaptor 1
HNRNPDL heterogeneous nuclear ribonucleoprotein D like
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
HSP90AA1 heat shock protein 90 alpha family class A member 1
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • DDX58/IFIH1-mediated induction of interferon-alpha/beta
  • vRNP Assembly
  • Regulation of actin dynamics for phagocytic cup formation
  • eNOS activation
  • Regulation of PLK1 Activity at G2/M Transition
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Sema3A PAK dependent Axon repulsion
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Anchoring of the basal body to the plasma membrane
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Downregulation of ERBB2 signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • RHOBTB2 GTPase cycle
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Constitutive Signaling by Overexpressed ERBB2
  • Aggrephagy
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Potential therapeutics for SARS
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Assembly and release of respiratory syncytial virus (RSV) virions
  • Respiratory syncytial virus genome replication
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • Quercetin
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • Tanespimycin
  • SNX-5422
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • CCT-018159
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Copper
  • Polaprezinc
  • Alvespimycin
HSP90B1 heat shock protein 90 beta family member 1
  • Trafficking and processing of endosomal TLR
  • Scavenging by Class A Receptors
  • Scavenging by Class A Receptors
  • ATF6 (ATF6-alpha) activates chaperone genes
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Interleukin-4 and Interleukin-13 signaling
  • Post-translational protein phosphorylation
  • Rifabutin
  • 2-Chlorodideoxyadenosine
  • Geldanamycin
  • Diglyme
  • N-Ethyl-5'-Carboxamido Adenosine
  • Radicicol
  • METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE
  • 2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE
  • Copper
ITGB1BP1 integrin subunit beta 1 binding protein 1
KAT5 lysine acetyltransferase 5
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • DNA Damage/Telomere Stress Induced Senescence
  • HATs acetylate histones
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Sensing of DNA Double Strand Breaks
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Estrogen-dependent gene expression
  • Defective homologous recombination repair (HRR) due to BRCA1 loss of function
  • Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function
  • Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function
  • Impaired BRCA2 binding to RAD51
  • Impaired BRCA2 binding to PALB2
  • Cardiogenesis
  • Coenzyme A
  • S-Acetyl-Cysteine

Page 2 out of 4 pages